<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00229632</url>
  </required_header>
  <id_info>
    <org_study_id>050245</org_study_id>
    <secondary_id>05-N-0245</secondary_id>
    <nct_id>NCT00229632</nct_id>
  </id_info>
  <brief_title>Idebenone to Treat Friedreich's Ataxia</brief_title>
  <official_title>A Six Month Double-Blind, Placebo-Controlled Phase 2 Clinical Trial to Determine the Safety and Efficacy of Idebenone Administered to Patients With Friedreich's Ataxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine whether a drug called idebenone is safe and effective in reducing&#xD;
      the level of oxidants that are believed to damage the nervous system and hearts in patients&#xD;
      with Friedreich's ataxia. Friedreich's ataxia is caused by an abnormality in the gene that&#xD;
      makes a protein called frataxin, which is necessary for the proper functioning of&#xD;
      energy-producing parts of cells called mitrochondria. In Friedreich's ataxia, the&#xD;
      mitochondria become overloaded with iron, and high levels of harmful compounds called&#xD;
      oxidants are formed. These oxidants are believed to damage the cells of the nervous system&#xD;
      and hearts of people with Friedreich's ataxia. Idebenone is a man-made drug similar to a&#xD;
      naturally occurring compound known as Coenzyme Q10. This study will test whether idebenone&#xD;
      can alleviate some of the symptoms of Friedreich's ataxia and slow or halt the progression of&#xD;
      the disease.&#xD;
&#xD;
      Patients with genetically confirmed Friedreich's ataxia who are between 9 and 18 years of&#xD;
      age, weigh between 65 and 175 pounds and can walk 25 feet with or without an assistive device&#xD;
      may be eligible for this study. Candidates are screened with blood tests and a review of&#xD;
      their medical records.&#xD;
&#xD;
      Participants undergo the following tests and procedures:&#xD;
&#xD;
        -  Medical interview and physical examination. Tests include blood and urine tests, an&#xD;
           electrocardiogram, or EKG (recording of the electrical activity of the heart),&#xD;
           echocardiogram (ultrasound test showing the pumping action of the heart, thickness of&#xD;
           the heart walls, and any valve leakage), and a detailed neurological examination,&#xD;
           including maneuvers such as copying a drawing and putting pegs in a board. Patients'&#xD;
           parents are asked questions about how they feel their child's disease affects the&#xD;
           child's quality of life.&#xD;
&#xD;
        -  Magnetic resonance imaging (MRI) to examine the heart muscle and blood flow to the&#xD;
           heart. MRI uses a magnetic field and radio waves to produce images of body tissues and&#xD;
           organs. The patient lies on a table that is moved into the doughnut-shaped MRI scanner,&#xD;
           wearing earplugs to muffle loud knocking and thumping sounds that occur during the&#xD;
           scanning process. A catheter (plastic tube) is placed in a vein in the child's arm so&#xD;
           that a chemical called gadolinium can be injected during the MRI study. Gadolinium&#xD;
           brightens areas of the heart, improving the ability to see the heart and blood flow.&#xD;
&#xD;
        -  Physical medicine and rehabilitation evaluations to test the child's physical&#xD;
           functioning. These tests include gait evaluation, measurements of the ability to exert&#xD;
           and maintain a constant force, assessment of visual-motor control and fine motor&#xD;
           control, aerobic exercise endurance testing, and measurement of the ability of the&#xD;
           child's heart and lungs to increase their effectiveness with exercise.&#xD;
&#xD;
        -  Idebenone/placebo treatment. Patients are given a 6-month supply of either idebenone&#xD;
           pills or placebo (pills that look like the study drug but have no active ingredient) to&#xD;
           take three times a day. Patients are seen by their primary care physician after 1 and 3&#xD;
           months on the study medication for a brief physical examination. In addition, they have&#xD;
           blood and urine tests once a month while on medication to check for any abnormalities.&#xD;
&#xD;
        -  6-month examination. After 6 months on the study drug, patients return to NIH to repeat&#xD;
           all the tests listed above to determine the effects of idebenone treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Friedreich's ataxia (FA) is a progressive, autosomal recessive, multisystem&#xD;
      degenerative disease for which there is currently no effective treatment. Recent studies have&#xD;
      suggested that lipid-soluble antioxidants lead to a modest reversal of cardiomyopathy in&#xD;
      patients with FA. It is possible that antioxidants may also prevent the progression of&#xD;
      neurodegeneration.&#xD;
&#xD;
      Objective: This will be a 6 month phase 2 double-blind, placebo-controlled trial to assess&#xD;
      the safety and efficacy of idebenone administered to adolescents and children with FA.&#xD;
&#xD;
      Study Population: We aim to enroll 48 subjects composed of children (ages 9-11) and&#xD;
      adolescents (ages 12-17) with FA divided evenly among 4 treatment arms (placebo, low,&#xD;
      intermediate, and high dose idebenone).&#xD;
&#xD;
      Design: Our primary objective is to examine the change in the level of oxidative stress by&#xD;
      measuring the oxidative marker 8-hydroxy-2-deoxyguanosine from baseline and after 6 months of&#xD;
      treatment with placebo or varying doses of idebenone. Following informed consent and assent,&#xD;
      patients will undergo an initial medical history and physical followed by specific&#xD;
      neurological, functional, and cardiac testing over a two-day outpatient visit. Patients will&#xD;
      provide blood and urine samples for safety laboratory and biochemical analysis. Each patient&#xD;
      will be randomized to one of 4 treatment arms and will be provided with a 6 month supply of&#xD;
      study drug or placebo which will be administered three times a day. Patients will have&#xD;
      follow-up laboratory monitoring after 1 and 3 months and at the end of the study.&#xD;
      Additionally, patients will also have an EKG, vital signs, including orthostatics, and a&#xD;
      physical examination performed after 1 and 3 months by their primary care physician. Patients&#xD;
      will return after 6 months for follow-up exam, testing, and laboratory monitoring over a&#xD;
      two-day outpatient visit.&#xD;
&#xD;
      Outcome Parameters: The primary endpoint in this phase 2 trial is the change in the level of&#xD;
      the oxidative stress marker 8-hydroxy-2-deoxyguanosine. Secondary endpoints include types and&#xD;
      frequency of adverse events, if any, compliance with the dosing regimen, and measurements of&#xD;
      the following: International Cooperative Ataxia Rating Scale (ICARS), Friedreich's ataxia&#xD;
      Rating Scale (FARS), force control, gait analysis, quantitative sensation testing, fine motor&#xD;
      control, health related quality of life score (SF-10), functional capacity, aerobic capacity,&#xD;
      left ventricular wall mass, noninvasive measures of systolic and diastolic ventricular&#xD;
      function, metabolic markers, markers of mitochondrial DNA damage, and gene expression&#xD;
      profiling.&#xD;
&#xD;
      Future Directions: We hope that the results of this phase 2 study will assist us in&#xD;
      developing a multi-center, double-blinded, placebo-controlled phase III trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 27, 2005</start_date>
  <completion_date type="Actual">December 17, 2007</completion_date>
  <primary_completion_date type="Actual">December 17, 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To examine the change in the level of oxidative stress by measuring the oxidative marker 8-hydroxy-2-deoxyguanosine from baseline and after 6 months of treatment with placebo or varying doses of idebenone</measure>
    <time_frame>baseline and after 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of idebenone</measure>
    <time_frame>baseline and after 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the effects of idebenone on cardiac parameters</measure>
    <time_frame>baseline and after 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the effects of idebenone on neurological function</measure>
    <time_frame>baseline and after 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effects of idebenone on patients quality of life</measure>
    <time_frame>baseline and after 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the effects of idebenone on functional capacity</measure>
    <time_frame>baseline and after 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate metabolic alterations, gene expression changes and markers of mitochondrial DNA damage</measure>
    <time_frame>baseline and after 6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">51</enrollment>
  <condition>Friedreich Ataxia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idebenone</intervention_name>
    <description>Idebenone is a short-chain benzoquinone derivative of similar structure to ubiquinone (coenzyme Q10). This compound was synthesized and developed initially by Takeda Chemical Industries, Ltd. (Osaka, Japan) and designated as CV-2619. The chemical name for idebenone is 6-(10-Hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benxoquinone. Santhera Pharmaceuticals (Liestal, Switzerland) LLC, will supply drug for this study as specified by a clinical trial agreement.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Diagnosis of FA with confirmed FRDA mutations.&#xD;
&#xD;
        Age from nine up to but not over eighteen years.&#xD;
&#xD;
        Weight between 30 to 80 kilograms.&#xD;
&#xD;
        Ambulatory (assistance devices permitted).&#xD;
&#xD;
        Willing to participate in all aspects of trial design and follow-up.&#xD;
&#xD;
        All subjects agree and commit to the use of 2 reliable methods of birth control for the&#xD;
        duration of the study if sexually active.&#xD;
&#xD;
        Neurologically symptomatic.&#xD;
&#xD;
        No exposure to idebenone, coenzyme Q10, or other dietary supplements for a period of at&#xD;
        least one month before enrollment in the study.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        History of a hypersensitivity reaction to idebenone or coenzyme Q10.&#xD;
&#xD;
        Pregnant or lactating women. All women of child-bearing potential must have negative serum&#xD;
        pregnancy prior to the medication phase of the study. If a minor has a positive pregnancy&#xD;
        test, we will inform her but not inform her parents unless we are asked to by the minor.&#xD;
&#xD;
        Platelet count, white blood cell count or hemoglobin below the lower limit of normal.&#xD;
&#xD;
        Alkaline phosphatase, SGOT, or SGPT greater than 1.5 times the upper limit of normal.&#xD;
        Bilirubin greater than 1.5 g/dl.&#xD;
&#xD;
        Creatinine greater than 1.5 times the upper limit of normal based upon the pediatric&#xD;
        reference range provided by the testing laboratory.&#xD;
&#xD;
        Clinically significant medical disease that, in the judgment of the investigators, would&#xD;
        expose the patient to undue risk of harm or prevent the patient from completing the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth H Fischbeck, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Neurological Disorders and Stroke (NINDS)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Harding AE. Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain. 1981 Sep;104(3):589-620.</citation>
    <PMID>7272714</PMID>
  </reference>
  <reference>
    <citation>DÃ¼rr A, Cossee M, Agid Y, Campuzano V, Mignard C, Penet C, Mandel JL, Brice A, Koenig M. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med. 1996 Oct 17;335(16):1169-75.</citation>
    <PMID>8815938</PMID>
  </reference>
  <reference>
    <citation>Hewer RL. Study of fatal cases of Friedreich's ataxia. Br Med J. 1968 Sep 14;3(5619):649-52.</citation>
    <PMID>5673214</PMID>
  </reference>
  <verification_date>March 14, 2019</verification_date>
  <study_first_submitted>September 29, 2005</study_first_submitted>
  <study_first_submitted_qc>September 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2005</study_first_posted>
  <last_update_submitted>March 15, 2019</last_update_submitted>
  <last_update_submitted_qc>March 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Friedreich's Ataxia</keyword>
  <keyword>Idebenone</keyword>
  <keyword>Ataxia</keyword>
  <keyword>Drug Trial</keyword>
  <keyword>Randomized Trial</keyword>
  <keyword>Friedreich Ataxia</keyword>
  <keyword>FA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Idebenone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

